TaqMan™ Oncology dPCR Multiplex Kit, BRAF V600

The Applied Biosystems TaqMan Oncology dPCR Multiplex Kit, BRAF V600, is a digital PCR (dPCR) multiplex kit designed for absolute quantification of BRAF V600 actionable biomarkers in oncology research. This turnkey solution comprises a multiplex dPCR assay and control material that enables simultaneous detection and quantification of V600E, V600R, and V600K mutations in a single reaction with high sensitivity suitable for liquid biopsy analysis.

The kit provides molecular pathologists and translational researchers with enhanced capabilities for oncology research and researching treatment solutions through its ease of use, fast turnaround time, and reliable results. Using the kit on the QuantStudio Absolute Q dPCR System with MAP16 plates and Absolute Q Universal DNA dPCR master mix enables results in as fast as two hours down to 0.1% variant allele frequency.

Features of the TaqMan Oncology dPCR Multiplex Kit, BRAF V600, include:

• Ready-to-use assay format—complete assay system delivered in a ready-to-use configuration, including controls. A streamlined, pipette-and-go workflow using MAP16 plates reduces preparation time and reduces potential for user error.
• Wet lab verified performance for high analytical sensitivity—the assay has undergone comprehensive wet laboratory testing on the Absolute Q dPCR System to verify analytical performance characteristics and reliability. It demonstrates superior detection capabilities for accurate identification of target analytes at low concentrations down to 0.1% VAF.
• Integrated quality controls—the included positive control alongside intra-reaction passive reference dye normalization helps ensure assay validity and enable quality assurance monitoring
• False positive protection—incorporates specific design elements to limit non-specific reactions and reduce false positive results. Running on the Absolute Q dPCR System also enables other false positive protection features like AI-backed false positive rejection and sophisticated background subtraction to enable more accurate quantification.

Streamlined workflow enables results in under two hours

The TaqMan Oncology dPCR Multiplex Kit, BRAF V600, features an exceptionally straightforward workflow that mirrors the simplicity of quantitative PCR (qPCR) protocols while helping deliver superior analytical performance. The complete process reduces hands-on time and consists of just a few essential steps to transition from sample to actionable results. Beginning with properly extracted DNA from liquid biopsy samples, users simply prepare the dPCR reaction using the provided assay components and universal master mix, load the MAP16 plate, transfer the plate to the Absolute Q instrument, and initiate the run. This optimized protocol helps enable comprehensive results in less than two hours, making it highly suitable for clinical research environments where rapid turnaround times are essential.

Gold standard TaqMan technology enhanced by advanced microfluidic arrays

The assay leverages the proven reliability of TaqMan probe-based chemistry, which represents the gold standard for precise quantification of nucleic acid targets in molecular research with over 200,000 citations. This established detection methodology is enhanced through integration with proprietary microfluidic array plate (MAP) technology, which helps deliver consistent and accurate quantification while simultaneously reducing dead volume, simplifying workflow complexity, and accelerating time to results. This combination of verified chemistry with innovative microfluidic engineering helps provide robust performance across diverse sample types and clinical research applications.

Ultra-sensitive detection with comprehensive quality controls

The system demonstrates exceptional analytical sensitivity, reliably detecting variant allele frequencies as low as 0.1%, making it particularly valuable for minimal residual disease (measurable residual disease) research and detection of rare circulating tumor DNA (ctDNA) variants in liquid biopsy specimens. The technology is especially useful alongside next-generation sequencing (NGS) platforms for researching and monitoring treatment response over time.

The ready-to-use kit format includes both optimized assays and essential controls, with all components thoroughly validated on the Absolute Q platform to help ensure consistent performance. Advanced software algorithms enable sophisticated false positive protection, enhancing the reliability of results and reducing the risk of erroneous clinical interpretations in your research. This comprehensive approach to quality control and validation supports confident decision-making in precision medicine research applications.